Arielle Yablonovitch
Research Subjects
Arielle Yablonovitch has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Charles Schneider
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
19 shared publications - Erica L. Carpenter
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
19 shared publications - Jacob E. Till
Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
19 shared publications - Jennifer Yen
Guardant Health, Redwood City, California
19 shared publications - Katherine L. Nathanson
Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
19 shared publications - Kim A. Reiss
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
19 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Patient-Level Data for Patients with Reversion Mutations
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Patient-Level Data for Patients with Reversion Mutations
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
ROC and Test Characteristics from VAF Analysis with Binary Outcome of 12-month OS
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
ROC and Test Characteristics from VAF Analysis with Binary Outcome of 12-month OS
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
VAF association with 12 month OS
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
VAF association with 12 month OS
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Representativeness of Study Participants
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Representativeness of Study Participants
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CtDNA-based enrollment PV detection and allelic status calls.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CtDNA-based enrollment PV detection and allelic status calls.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CHRD scores based on tumor type, genotype and tumor or ctDNA-derived allelic status.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
CHRD scores based on tumor type, genotype and tumor or ctDNA-derived allelic status.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Details of reversion alterations in reversion evaluable patients
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
Details of reversion alterations in reversion evaluable patients
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
IGV screenshots for two patients with ATM reversions.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors
IGV screenshots for two patients with ATM reversions.